Enlivex Ltd.

ENLV Healthcare Biotechnology

In the quarter to June 2026, EPS grew 5,185.1% and free cash flow grew 35.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.21 0.01 −4.55%
Market cap
$4.5M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Jun '25 Sep '25 Dec '25 Jun '26
Current Ratio

+8 more quarters

6.41 6.43 193.24 119.39
Net Debt/EBITDA
6.52 7.35 300.51 881.46
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.76) (1.24) (0.86) 0.00
Book value per Share
11.98 10.90 634.85 235.67
Free Cash Flow
(1.20) (1.99) (2.63) —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026